Basics Geron Corporation Geron Corp is a biopharmaceutical company. It supports the clinical stage development of a telomerase inhibitor, imetelstat. IPO Date: July 31, 1996 Sector: Healthcare Industry: Biotech Market Cap: $910.79M Activated in VL: True Average Daily Range Avg Daily Range: $0.11 | 2.88% Avg Daily Range (30 D): $0.05 | 3.76% Avg Daily Range (90 D): $0.06 | 3.07% Institutional Daily Volume Avg Daily Volume: 2.7M Avg Daily Volume (30 D): 11.97M Avg Daily Volume (90 D): 13.03M Trade Size Avg Trade Size (Sh.): 343 Avg Trade Size (Sh.) (30 D): 543 Avg Trade Size (Sh.) (90 D): 537 Institutional Trades Total Inst.Trades: 2,565 Avg Inst. Trade: $1.88M Avg Inst. Trade (30 D): $1.45M Avg Inst. Trade (90 D): $1.97M Avg Inst. Trade Volume: .6M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $2.41M Avg Closing Trade (30 D): $1.44M Avg Closing Trade (90 D): $2.08M Avg Closing Volume: 807.8K         News May 9, 2025 @ 1:00 PM INVESTOR ALERT: Pomerantz Law Firm Investigates Cl... Source: Pomerantz Llp May 9, 2025 @ 12:00 PM INVESTOR ALERT: Pomerantz Law Firm Announces the F... Source: N/A May 7, 2025 @ 8:35 PM Why Geron Stock Crept Higher Today Source: Eric Volkman May 7, 2025 @ 2:35 PM GERN Investors are Reminded of an Opportunity to L... Source: Prnewswire May 5, 2025 @ 10:22 PM GERN DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING L... Source: N/A Financials   TTM Q1 2025 Q4 2024 Basic EPS $-.21 $-.03 $-.04 Diluted EPS $-.21 $-.03 $-.04 Revenue $ 116.29M $ 39.6M $ 47.54M Gross Profit $ $ $ Net Income / Loss $ -139.02M $ -19.84M $ -25.35M Operating Income / Loss $ -134.3M $ -16.7M $ -20.05M Cost of Revenue $ $ $ Net Cash Flow $ -105.26M $ 4.73M $ 18.71M PE Ratio